BIOGEN IDEC: Dispute with Sanofi Over Enhancer Patents Ongoing

Biogen Idec Inc. and Genentech Inc. remain in dispute with Sanofi- Aventis Deutschland GmbH over the alleged infringement of U.S. Patents 5,849,522 and 6,218,140.

Both patents relate to enhancers for eukaryotic…

BIOGEN IDEC: Hoechst Royalties Arbitration v. Genentech Ongoing

Genentech Inc. continues to be involved in an arbitration proceeding filed by Hoechst GmbH seeking royalties, according to Biogen Idec Inc.’s latest Quarterly Report filed with the U.S. Securities and…